NTQ 5082
Alternative Names: NTQ-5082Latest Information Update: 18 Sep 2024
At a glance
- Originator Nanjing Chia Tai Tianqing Pharmaceutical
- Class Antianaemics; Small molecules
- Mechanism of Action Complement factor B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological disorders
Most Recent Events
- 27 Aug 2024 Nanjing Chia Tai Tianqing Pharmaceutical plans a food effect phase I trial (In Volunteers) in China (PO, Capsule) in August 2024 (NCT06558656)
- 19 Aug 2024 Preclinical trials in Haematological disorders in China (PO) prior to August 2024
- 19 Aug 2024 Nanjing Chia-tai Tianqing Pharmaceutical plans a PK/PD/safety phase I trial (In volunters) in China (PO, Capsule) in August 2024 (NCT06560593)